Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | TERT | O14746 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | PPARD | Q03181 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | TOP1 | P11387 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493669 | 1.00 | EP300 (0.60) | EP300TSHRTERTPTPN1PPARG | |
| SCHEMBL1574053 | 1.00 | EP300 (0.60) | EP300TSHRTERTPTPN1PPARG | |
| SCHEMBL15351850 | 1.00 | EP300 (0.60) | EP300TSHRTERTPTPN1PPARG | |
| SCHEMBL9189355 | 1.00 | EP300 (0.60) | EP300TSHRTERTPTPN1PPARG | |
| SCHEMBL3677161 | 1.00 | EP300 (0.60) | EP300TSHRTERTPTPN1PPARG | |
| SCHEMBL3085238 | 1.00 | EP300 (0.60) | EP300TSHRTERTPTPN1PPARG | |
| SCHEMBL7103277 | 1.00 | EP300 (0.60) | EP300TSHRTERTPTPN1PPARG | |
| SCHEMBL15350784 | 1.00 | EP300 (0.60) | EP300TSHRTERTPTPN1PPARG | |
| SCHEMBL15350839 | 1.00 | EP300 (0.60) | EP300TSHRTERTPTPN1PPARG | |
| SCHEMBL28908165 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530603-B2 | Golf ball | SRI SPORTS LIMITED (JP) | 2013-09-10 | — | — | US | claimed |
| US-20240376256-A1 | ORGANIC BINDER, COMPOSITION FOR PRODUCING INORGANIC MATERIAL MOLDED ARTICLE, GREEN BODY, DEGREASED BODY, INORGANIC MATERIAL MOLDED ARTICLE, AND METHOD OF PRODUCING INORGANIC MATERIAL MOLDED ARTICLE | KUREHA CORPORATION (JP) | 2024-11-14 | — | — | US | disclosed |
| CN-114269888-B | Fragrance enhancing composition | 阿尔门德拉私人有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-11963939-B2 | Use of N-acetylcysteine to treat central nervous system disorders | Neuronasal, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240115533-A1 | USE OF N-ACETYLCYSTEINE TO TREAT CNS DISORDERS | Burke Neurological Institute | 2024-04-11 | — | — | US | disclosed |
| CN-117529377-A | Organic binder, composition for producing inorganic material molded body, green body, degreased body, inorganic material molded body, and method for producing inorganic material molded body | 株式会社吴羽 | 2024-02-06 | — | — | CN | disclosed |
| US-20230414548-A1 | USE OF N-ACETYLCYSTEINE TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | NEURONASAL, LLC | 2023-12-28 | — | — | US | disclosed |
| WO-2023147169-A2 | NOVEL LIQUID FORMULATIONS FOR IRON CHELATION | LIVIONEX, Inc. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-11707648-B2 | Golf ball | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2023-07-25 | — | — | US | disclosed |
| US-11660278-B2 | Use of N-acetylcysteine to treat central nervous system disorders | Neuronasal, Inc. (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2012001687-A2 | A NEUROPROTECTIVE NATURAL EXTRACT | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2012-01-05 | — | — | WO | disclosed |
| US-20100331113-A1 | GOLF BALL | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100150895-A1 | Nutraceutical agent for attenuating the Neurodegenerative process associated with Parkinson's disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-17 | — | — | US | disclosed |
| US-20090111121-A1 | METHOD FOR DETECTING A BIOMARKER OF OXIDATIVE STRESS IN A BIOLOGICAL SAMPLE | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2009-04-30 | — | — | US | disclosed |
| CN-101379396-A | Method for detecting biomarkers of oxidative stress in biological samples | INST CARDIOLOGIE MONTREAL (CA) | 2009-03-04 | — | — | CN | disclosed |
| EP-1934602-A4 | METHOD FOR DETECTING A BIOMARKER OF OXIDATIVE STRESS IN A BIOLOGICAL SAMPLE | INST CARDIOLOGIE MONTREAL (CA) | 2009-01-21 | — | — | EP | disclosed |
| US-20080292607-A1 | Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease | MAZZIO ELIZABETH | 2008-11-27 | — | — | US | disclosed |
| EP-1934602-A1 | METHOD FOR DETECTING A BIOMARKER OF OXIDATIVE STRESS IN A BIOLOGICAL SAMPLE | Institut de Cardiologie de Montréal (CA) | 2008-06-25 | — | — | EP | disclosed |
| US-20070116779-A1 | Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease | MAZZIO ELIZABETH | 2007-05-24 | — | — | US | disclosed |
| WO-2007041868-A1 | METHOD FOR DETECTING A BIOMARKER OF OXIDATIVE STRESS IN A BIOLOGICAL SAMPLE | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414548-A1 | USE OF N-ACETYLCYSTEINE TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | NLN, ALOX5, AANAT | EP300 1531/4885TSHR 3198/4885TERT 2483/4885 |
| US-11963939-B2 | Use of N-acetylcysteine to treat central nervous system disorders | NLN, ALOX5, AANAT | EP300 1531/4885TSHR 3198/4885TERT 2483/4885 |
| US-11660278-B2 | Use of N-acetylcysteine to treat central nervous system disorders | NLN, ALOX5, AANAT | EP300 1531/4885TSHR 3198/4885TERT 2483/4885 |
| US-20240115533-A1 | USE OF N-ACETYLCYSTEINE TO TREAT CNS DISORDERS | AANAT, ALOX5, PRSS12 | EP300 1391/4885TSHR 3618/4885TERT 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.